Thana, M., Basappa, N. S., Ghosh, S., Kollmannsberger, C. K., Heng, D. Y. C., Hansen, A. R., Graham, J., Soulières, D., Reaume, M. N., Lalani, A. K. A., Castonguay, V., Bjarnason, G. A., Patenaude, F., Breau, R. H., Pouliot, F., Kapoor, A., & Wood, L. A. (2022). Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. Clinical Genitourinary Cancer, 20(3), 210-218. https://doi.org/10.1016/j.clgc.2021.12.003
Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. / Thana, Myuran; Basappa, Naveen S.; Ghosh, Sunita et al.
In:
Clinical Genitourinary Cancer, Vol. 20, No. 3, 06.2022, p. 210-218.
Research output: Contribution to journal › Article › peer-review
Thana, M, Basappa, NS, Ghosh, S, Kollmannsberger, CK, Heng, DYC, Hansen, AR, Graham, J, Soulières, D, Reaume, MN, Lalani, AKA, Castonguay, V, Bjarnason, GA, Patenaude, F, Breau, RH, Pouliot, F, Kapoor, A & Wood, LA 2022, 'Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients', Clinical Genitourinary Cancer, vol. 20, no. 3, pp. 210-218. https://doi.org/10.1016/j.clgc.2021.12.003
Thana M, Basappa NS, Ghosh S, Kollmannsberger CK, Heng DYC, Hansen AR et al. Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. Clinical Genitourinary Cancer. 2022 Jun;20(3):210-218. doi: 10.1016/j.clgc.2021.12.003
Thana, Myuran ; Basappa, Naveen S. ; Ghosh, Sunita et al. / Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. In: Clinical Genitourinary Cancer. 2022 ; Vol. 20, No. 3. pp. 210-218.
@article{54fae79b6e184d77ac4ca96bacd836de,
title = "Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients",
keywords = "Immune checkpoint inhibitors, Immune-related adverse effects, Immuno-oncology, Immunotherapy, Retrospective",
author = "Myuran Thana and Basappa, {Naveen S.} and Sunita Ghosh and Kollmannsberger, {Christian K.} and Heng, {Daniel Y.C.} and Hansen, {Aaron R.} and Jeffery Graham and Denis Souli{\`e}res and Reaume, {Martin Neil} and Lalani, {Aly Khan A.} and Vincent Castonguay and Bjarnason, {Georg A.} and Fran{\c c}ois Patenaude and Breau, {Rodney H.} and Fr{\'e}d{\'e}ric Pouliot and Anil Kapoor and Wood, {Lori A.}",
note = "Publisher Copyright: {\textcopyright} 2021",
year = "2022",
month = jun,
doi = "10.1016/j.clgc.2021.12.003",
language = "English",
volume = "20",
pages = "210--218",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "3",
}
TY - JOUR
T1 - Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients
AU - Thana, Myuran
AU - Basappa, Naveen S.
AU - Ghosh, Sunita
AU - Kollmannsberger, Christian K.
AU - Heng, Daniel Y.C.
AU - Hansen, Aaron R.
AU - Graham, Jeffery
AU - Soulières, Denis
AU - Reaume, Martin Neil
AU - Lalani, Aly Khan A.
AU - Castonguay, Vincent
AU - Bjarnason, Georg A.
AU - Patenaude, François
AU - Breau, Rodney H.
AU - Pouliot, Frédéric
AU - Kapoor, Anil
AU - Wood, Lori A.
N1 - Publisher Copyright:
© 2021
PY - 2022/6
Y1 - 2022/6
KW - Immune checkpoint inhibitors
KW - Immune-related adverse effects
KW - Immuno-oncology
KW - Immunotherapy
KW - Retrospective
UR - http://www.scopus.com/inward/record.url?scp=85123871032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123871032&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2021.12.003
DO - 10.1016/j.clgc.2021.12.003
M3 - Article
AN - SCOPUS:85123871032
SN - 1558-7673
VL - 20
SP - 210
EP - 218
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 3
ER -
